What Oncology Nurses Need to Know About Subcutaneous Rituxan Hycela

In June 2017, the U.S. Food and Drug Administration (FDA) approved Rituxan Hycela™, a combination of rituximab and hyaluronidase, for subcutaneous administration in the treatment of follicular lymphoma and diffuse large B-cell lymphoma as well as chronic lymphocytic leukemia (CLL). This agent affords the same clinical benefit as IV rituximab, but in much less time. With this approval comes many questions about which patients are appropriate and administration considerations for subcutaneous rituximab and hyaluronidase.